Michallet, A., Dilhuydy, M., Subtil, F., Rouille, V., Mahe, B., Laribi, K., Villemagne, B., Salles, G., Tournilhac, O., Delmer, A., Portois, C., Pegourie, B., Leblond, V., Tomowiak, C., de Guibert, S., Orsini, F., Banos, A., Carassou, P., Cartron, G., Fornecker, L. M., Ysebaert, L., Dartigeas, C., Truchan Graczyk, M., Vilque, J. P., Aurran, T., Cymbalista, F., Lepretre, S., Lévy, V., Nguyen-Khac, F., Le Garff-Tavernier, M., Aanei, C., Ticchioni, M., Letestu, R., & Feugier, P. (2019). obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial. Lancet, 6(9), e470–e479. http://access.bl.uk/ark:/81055/vdc_100091256508.0x000008